| CASE REPORT |
|
| Year : 2022 | Volume
: 9
| Issue : 1 | Page : 22-25 |
|
|
Immune-related neuromuscular junction disorder after immune checkpoint inhibitor treatment
Shang-Hsuan Peng1, Yu-Yun Shao2
1 >Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
Correspondence Address:
Dr. Yu-Yun Shao
Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_26_21
|
|
|
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and prolonged the survival of patients with various malignancies. Nevertheless, the expanded usage of ICIs is associated with increased reports of immune-related adverse events (irAEs), some of which can impair functional outcomes and worsen the prognosis. We present a fatal case of a patient presenting with progressive generalized weakness diagnosed with immune-related neuromuscular junction (NMJ) disorder after nivolumab treatment. By describing this case, we hope to raise awareness of rare irAEs such as immune-related NMJ disorder because prompt intervention is essential to minimize long-term sequelae and improve outcomes.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
